Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Preferred Stock Liabilities (2018)

Historic Preferred Stock Liabilities for 10x Genomics (TXG) over the last 1 years, with Q4 2018 value amounting to $243.2 million.

  • 10x Genomics' Preferred Stock Liabilities changed N/A to $243.2 million in Q4 2018 from the same period last year, while for Dec 2018 it was $243.2 million, marking a year-over-year change of. This contributed to the annual value of $243.2 million for FY2018, which is N/A changed from last year.
  • 10x Genomics' Preferred Stock Liabilities amounted to $243.2 million in Q4 2018.
  • In the past 5 years, 10x Genomics' Preferred Stock Liabilities registered a high of $243.2 million during Q4 2018, and its lowest value of $243.2 million during Q4 2018.